Overview
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Eligibility
Key Inclusion Criteria:
- Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Key Exclusion Criteria:
- Participants with primary platinum-refractory disease.
Note: Other protocol-defined inclusion/exclusion criteria may apply.